In postmenopausal women with advanced HR+, HER2-negative breast cancer when letrozole or anastrozole fails,
Prescribe AFINITOR plus exemestane to...
Up to 70% of cases of breast cancer have mutations in the PI3K/Akt/mTOR pathway; hyperactivation of this pathway can contribute to endocrine resistance.1-5
Double Median PFS
Median PFS was 7.8 months [95% CI, 6.9-8.5] with AFINITOR® (everolimus) Tablets plus exemestane vs 3.2 months [95% CI, 2.8-4.1] with placebo plus exemestane (HR=0.45 [95% CI, 0.38-0.54]; P<0.0001).6
Excerpts from the experts
Victoria: A Case Study of HR+, HER2-Negative Advanced Breast Cancer Following Progression on NSAI Therapy
Kimberly Blackwell, MD
Professor of Medicine
Richard Michaelson, MD
Chief Medical Officer for Oncology
Saint Barnabas Medical Center
Diane: A Case Study of HR+, HER2-Negative Advanced Breast Cancer Following Progression on NSAI Therapy
Ingrid Mayer, MD
Breast Cancer Specialist
Vanderbilt University Medical Center
Allan Lipton, MD
Professor of Oncology
Milton S. Hershey Medical Center
Ellen: A Case Study of Progression to the Viscera Following NSAI Therapy in HR+, HER2-Negative Advanced Breast Cancer
Nancy Peacock, MD
Denise A. Yardley, MD
Medical Oncologist, Senior
Sarah Cannon Research Institute
Coverage and support* from the very beginning
Our program provides comprehensive support to you and your patients throughout the treatment journey with AFINITOR. Get appropriate patients started on treatment promptly with a 14-day free trial of AFINITOR, the $25 AFINITOR Co-Pay Card or foundational assistance, and coverage support from our reimbursement experts.
*Eligibility requirements exist for all components for the AFINITOR Patient Support Program.
Is it time for a different treatment approach?
In the BOLERO-2 trial, following progression on an NSAI,
of patients in the endocrine monotherapy arm were estimated to have progressed at 3.2 months.6
Abbreviations: BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; MOA, mechanism of action; mTOR, mammalian target of rapamycin; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival.